B·R·A·H·M·S™ CgA II KRYPTOR™

Thermo Scientific™ B·R·A·H·M·S™ CgA II KRYPTOR™ is an automated immunofluorescent assay using Time-Resolved amplified Cryptate Emission (TRACE™) technology to determine the concentration of Chromogranin A (CgA) in human serum. B·R·A·H·M·S CgA II KRYPTOR is indicated as an aid to be used in conjunction with clinical evaluation for follow-up and monitoring of patients with neuroendocrine tumors (NETs) and for therapy monitoring of patients with prostate cancer. The test is further indicated as an aid to be used in conjunction with clinical evaluation for the diagnosis of patients with suspected pheochromocytomas. Please consult the Instructions For Use (IFU) available in your country.

Intended Use for US only: B·R·A·H·M·S CgA II KRYPTOR is to be used in conjunction with other clinical methods as an aid in monitoring of disease progression during the course of disease and treatment in patients with gastroentero-pancreatic neuroendocrine tumors (GEP-NETs, grade 1 and grade 2).

• Chromogranin A is an acidic, hydrophilic protein of 49 kDa present in chromaffin granules of the neuroendocrine cells and is a member of the granin family.
• Neuroendocrine tumors (NETs) originate from neuroendocrine cells found in neuronal and endocrine tissues throughout the body.
• The most common sites of NETs are the lung, stomach, appendix, cecum, duodenum, pancreas, jejunum/ileum, colon and rectum.
• NETs arising from the gastrointestinal tract are collectively known as gastroentero-pancreatic neuroendocrine tumors.
• Follow up and monitoring investigations of NETs are based on tumor markers together with other diagnostic measures and clinical signs.
• Besides its use as immunohistological marker, CgA has been well recognized as a general broad-spectrum serum marker in GEP-NETs.